COMMUNIQUÉS West-GlobeNewswire

Photocure ASA: Landmark Blue Light Cystoscopy with Cysview® study is published in the Journal of Urology

08/12/2017 - 08:20

Oslo, Norway, December 8, 2017: Photocure ASA (Photocure, PHO: OSE), today announced that the official Journal of the American Urologic Association (AUA), the Journal of Urology, published the BLFCC Efficacy results [...]

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

08/12/2017 - 07:30

Resources redirected to progress new drug candidates to clinic in H1 2018 Press release Leuven, Belgium, 8 December 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines [...]

Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine

08/12/2017 - 07:15

Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a long-acting version of the [...]

Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

08/12/2017 - 01:25

- Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously in Favor of Unified IC/BPS Population for Clinical Trials - SILVER SPRING, Md., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , [...]

Denali Therapeutics Announces Pricing of Initial Public Offering

08/12/2017 - 01:08

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ) today announced the pricing of its initial public offering of 13,888,888 shares of its common stock at a price to [...]

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

08/12/2017 - 00:30

-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 [...]

MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

08/12/2017 - 00:00

LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Mesoblast Named Global Technology Leader in Cell Therapy Industry

07/12/2017 - 23:33

NEW YORK and MELBOURNE, Australia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. [...]

Skyline Medical Issues Letter to Shareholders

07/12/2017 - 23:00

MINNEAPOLIS, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ: SKLN ) (“Skyline” or the “Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, [...]

Gilead Sciences to Acquire Cell Design Labs

07/12/2017 - 23:00

– Demonstrates Gilead’s Deep Commitment to Cell Therapy – – Novel Cell Engineering Technologies with the Potential to Drive Discovery and Development of New Anti-Cancer Medicines – – Structured Buy Out to Acquire Cell [...]

National Research Corporation Declares Quarterly Dividend

07/12/2017 - 23:00

Lincoln, Nebraska, Dec. 07, 2017 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA and NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per [...]

Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee

07/12/2017 - 22:35

BURLINGTON, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics (PK) and safety of [...]

The Cooper Companies Announces Fourth Quarter and Full Year 2017 Results

07/12/2017 - 22:15

PLEASANTON, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE: COO ) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2017. Fourth quarter revenue [...]

Intercept to Present at Upcoming Conference

07/12/2017 - 22:05

NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]

Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock

07/12/2017 - 22:05

TUSTIN, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) (Nasdaq: PPHMP ) today announced that its Board of Directors has declared a quarterly cash dividend payment on the [...]

Optinose to Present at BMO Capital Markets Prescription for Success Healthcare Conference

07/12/2017 - 22:05

YARDLEY, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller [...]

Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

07/12/2017 - 22:05

AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with [...]

Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer

07/12/2017 - 22:05

SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ: CASC ), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of care agents [...]

Fennec Announces Proposed Public Offering of Common Shares

07/12/2017 - 22:01

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) (TSX: FRX ), a biotechnology company focused on the development of PEDMARK™ (a unique formulation of sodium [...]